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Summary
Objectives. To describe clinical manifestations and performed diagnostic workup, fo-
cusing on drug challenge tests (DCT), in patients with drug allergy. Methods. Ret-
rospective study including all patients with skin tests (STs) or DCT-based drug allergy 
diagnosis between 01/2014 - 06/2018 in a Portuguese allergy unit. Data were collect-
ed from electronic and paper-based clinical records. Results. We had 75 drug allergy 
diagnoses. Most index reactions were mild and ≥ 1 hour after drug intake. Fifty-nine 
(78%) diagnoses were based on DCTs, all based on multistep protocols with ≥ 3 pre-
dicted steps. Only 10% of the DCT were positive during up-dosing; timing and severity 
of the index reaction predicted DCT interruption during up-dosing. Conclusions. 
Most drug allergy diagnoses were based on multistep DCT. The identified predictors of 
DCT interruption during up-dosing can support the development of more personalized 
DCTs protocols.
sequentially. However, the precise cut-off to differentiate imme-
diate from nonimmediate reactions is controversial (2-5).
DHRs are often self-reported as “drug allergy” and not con-
firmed by appropriate assessment. This is a frequent problem 
in daily clinical practice and has a considerable impact on pre-
scription choices and patient health. In fact, many more pa-
tients suspect they have a DHR than can be confirmed, in-
dicating the importance of an accurate diagnosis of DHRs, 
which will facilitate appropriate treatment options and pre-
ventive measures (6). If the reaction is A-type, it is likely that 
the primary care physician will be able to manage it within 
the practice, however if it is a B-type reaction, it will require a 
structured diagnostic process by an allergy specialist (6,7). The 
diagnostic approach to DHRs may include a detailed clinical 
history, followed by skin tests (ST), in vitro tests, and drug 
challenge tests (DCT).
Introduction
The term “drug allergy” is widely used in a popular sense to 
encompass both some type A reactions, which are predictable 
side effects due to the drug’s pharmacological action, and type 
B reactions, which represent true hypersensitivity due to idio-
syncratic and individual predisposition (1). However, the defi-
nite classification of a drug hypersensitivity reaction (DHR) is 
important for determining appropriate diagnostic procedures; 
immunological drug reactions can be divided into two broad 
types, as recommended by the World Allergy Organization 
(WAO) (1). These categories are based on the timing of the 
symptoms’ onset: immediate DHRs occur within the first hours 
of the first administered dose and are usually IgE-mediated, 
while nonimmediate DHRs occur anytime thereafter; most of 
these reactions are cell-mediated hypersensitivities and involve 
several unknown mechanisms, which act simultaneously or even 
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Since clinical history can be unreliable, the sensitivity of in vitro 
tests may be suboptimal and ST are not feasible nor validated 
for all drugs, a definitive diagnosis of drug hypersensitivity fre-
quently relies on DCT (8). This test (double blinded, placebo 
controlled) is widely considered the gold standard for establish-
ing or ruling out drug hypersensitivity. Moreover, it is also of 
major importance for assessing tolerance to potentially cross-re-
active drugs and for providing alternative drugs (8). DCTs in-
volve the controlled administration of a drug under medical 
surveillance. Therefore, it is a time-consuming and costly exam. 
A base-case penicillin allergy evaluation including skin testing 
followed by DCT is estimated to cost $ 220 (9). Evaluation of 
all Americans who report penicillin allergy would cost over $ 7 
billion using this protocol (9-11).
There are a few published protocols for DCTs, but there is lack of 
information on the best protocol to use with each patient. In clin-
ical practice, the diagnostic approach taken is highly inconsistent 
despite efforts from the scientific community to create clear-cut 
algorithms. In most European countries the diagnostic assess-
ment takes place in specialized centers and is adapted depending 
on the drug involved and the type of allergic reaction suspected 
(e.g. immediate or non-immediate) (6). Different protocols have 
been described for immediate and nonimmediate DHRs, with 
some studies reporting increased diagnostic accuracy when pro-
longed DCTs are used in individuals with nonimmediate DHRs 
reactions (12-16). However, even in these nonimmediate DHRs 
tested with prolonged DCT protocols and having mean reaction 
delays > 48 hours (17,18), most studies report long first day, of-
fice-based, supervised oral DCTs, with multiple increasing doses 
that could possibly be shortened; this would result in decreased 
utilization of time and resources. Studies describing diagnostic 
procedures that confirmed drug allergy and reporting the predic-
tors of DCT positivity during up-dosing are lacking; however, 
this could give valuable data to inform if shorter protocols for 
DCT could be safely used, at least in some patients. 
With the present study, we aimed to: 1) describe drug allergy 
manifestations in patients with ST or DCT-based drug allergy 
diagnosis; 2) describe the diagnostic procedures that were per-
formed to objectively diagnose drug allergy, focusing DCTs; and 
3) estimate the proportion of DCTs interrupted before reaching 
the target cumulative dose, to describe the reacting dose/step 
and to make an exploratory analysis of the predictors of DCT 
interruption during up-dosing.
Material and methods
Study design and data collection
This was an observational, retrospective study held in a private 
allergy unit from Northern Portugal. All patients that had drug 
allergy confirmed by ST or DCTs between January 2014 and 
June 2018 were eligible for inclusion. Patients with allergic con-
tact dermatitis to drugs were excluded.
Data were collected from the electronic medical records, the fi-
nal patient report and the specific DCT paper-forms that are 
used in the usual clinical practice for data registry; these paper 
forms include the prespecified protocol, doses administered, the 
symptoms and objective clinical manifestations arising during 
DCTs, and DCT outcome. Data was collected considering the 
variables suggested in the ENDA questionnaire (19). 
All patients gave written informed consent to perform the di-
agnostic procedures. The collected data was anonymized before 
analysis. 
Diagnostic procedures
The drug allergy workup was performed according to the phy-
sician’s judgment, based on the EAACI guidelines on drug aller-
gy diagnosis (4) and adapted according to the patient’s history. 
The approach to a patient with suspected drug allergy involves a 
thorough characterization of the index reaction by the physician 
and, eventually, performing ST (skin prick tests, intradermal 
tests, patch tests), in vitro tests (e.g. specific IgE), and DCTs. 
ST were done and interpreted according to the recommenda-
tions from Brockow et al. (20). ST were predominantly per-
formed with drugs that have published validated concentra-
tions (e.g. betalactams). However, in a few patients, especially 
in those who presented severe immediate index reactions, ST 
were performed with drugs without fully validated ST concen-
trations; in these cases, a literature review was performed prior 
to ST and the tested concentrations were selected according to 
the best available evidence. In patients with compatible index 
reaction performing ST with previously published non-irri-
tant drug concentrations (even if not fully validated), especially 
if the suspected drug was not amenable to DCT, positive ST 
were considered sufficient to diagnose drug allergy. ST were not 
routinely performed when the suspected mechanism underly-
ing the index reaction was not suggestive of being amenable to 
study with ST (e.g. most reactions with NSAIDs) (4). 
DCTs were performed using multistep protocols, with admin-
istration of progressively higher doses of the suspected or alter-
native drug. DCT were continued until the therapeutic dose 
was reached, an objective adverse reaction arisen, or the patient 
revoked consent for the procedure. In our unit, all DCT are per-
formed under medical supervision in a day ward setting. The 
usual DCT protocol depends on the drug and can be adapted ac-
cording to the patient history or symptoms during the challenge; 
when available, previously published protocols were preferred. 
All DCT included an extended watching period with length 
adapted to the severity and time of onset of the index reaction.
Patients with late reactions described as maculopapular exan-
thems had extended DCTs (at least three days of outpatient 
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drug intake), according to the findings of some recent studies, 
both in pediatric (12,13,18,21) and adult (12,14-16) popula-
tions. Most patients with late reactions described as maculopap-
ular exanthems (e.g. to betalactams), performed DCT without 
previous ST (12).
DCTs were considered positive based on the presence of objec-
tive signs and reproducibility between DCT and index reaction. 
When the patient presented no objective signs or nonreproduc-
ible minor symptoms, the DCT was considered inconclusive 
and was not included in this analysis.
Patients with severe cutaneous manifestations (4,22), including 
Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis 
(TEN), acute generalised exanthematous pustulosis (AGEP), 
vasculitis or drug reaction with eosinophilia and systemic symp-
toms (DRESS) were not considered for diagnostic DCT.
Variables and classifications
The up-dosing phase of the DCT was considered completed if 
the predefined target cumulative dose (at least one therapeutic 
dose of the specific drug) was reached. When this dose was not 
attained, the up-dosing phase was considered as interrupted.
Cutaneous drug hypersensitivity reactions were classified ac-
cording to the EAACI recommendations (22). 
The severity of systemic reactions was classified according to 
the classification proposed by Cox et al. (23), including 5 dif-
ferent grades. This classification system intends to be a com-
mon way to describe the severity of systemic allergic reactions, 
applicable not only to immunotherapy (as the WAO classifi-
cation system (24)), but also to drug, food or venom allergy. 
However, it seems primarily designed to classify severity of im-
mediate reactions and does not clearly state that can be applied 
to delayed DHR. In this study, this classification system was 
used irrespectively of the time of reaction onset. 
The cut-off to define immediate and nonimmediate drug al-
lergy is still controversial: Levine et al. (5) defined immedi-
ate reactions as those beginning < 2 hours after drug intake, 
accelerated between 2 and 48 h, and delayed after 48 hours; 
Romano et al. (2) considered immediate beginning ≤ 1 hour 
and non-immediate > 1 hour; other authors (3,4,25) reported 
that immediate reactions can begin until 6 hours of drug intake 
and nonimmediate anytime thereafter. To perform exploratory 
analysis including all these different possible cut-offs, we classi-
fied the timing of index and DCT reactions into 5 classes (≤ 1 
hour, 1 to 2 hours, 2 to 6 hours, 6 to 48 hours, and > 48 hours). 
Statistical analysis
Data was analysed by patient and by drug allergy diagnosed. In 
patients with more than one reaction to the same drug, the most 
recent was included in the descriptions.
Categorical data was described with absolute and relative fre-
quencies and continuous variables (age) with mean and stan-
dard deviation (SD). Pearson chi-square was used for compar-
ison of proportions when all categories had n > 5; in very small 
groups (at least one category with n ≤ 5) a 2-sided Fisher’s 
exact test was used. Variables organized as trend were analysed 
with linear-by-linear association chi-square. Comparisons of 
continuous variables, due to the small sample size and variable 
distribution, were performed using non-parametric tests, in-
cluding Kruskal-Wallis (for k independent samples) and Mann 
Whitney U (for 2 independent samples).
Agreement between categorical variables was assessed with Co-
hen’s kappa (K). The K value was interpreted as follows (26): 
< 0.20 poor; 0.20 to 0.40 fair; 0.41 to 0.60 moderate; 0.61 to 
0.80 good; 0.81 to 1.00 very good. 
We used CART (classification and regression tree) analysis to 
identify the most important predictors of DCT outcome during 
up-dosing. CART is a nonparametric supervised classification 
method that is intended as an exploratory tool to discover homo-
geneous subgroups within the data; it is appealing because of the 
apparent closeness to the human reasoning processes, presenting 
data in easy to interpret tree models (27). We performed CART 
analysis using Gini impurity index to grow the trees and the 
cost-complexity pruning algorithm to generate a simpler tree. The 
chosen result is within one standard error of the tree with best er-
ror estimate, favouring trees with minimum costs. The predictors 
included in CART were selected based on an unadjusted analy-
sis that identified the variables significantly associated with DCT 
outcome during up-dosing. The variable importance was given by 
Gini index, where the highest value is 100%. Variables that did not 
contribute significantly to the model were automatically removed. 
CART analysis was performed with Salford Predictive Model-
er® version 8.2 (Salford Systems, San Diego, USA). All other 
data analyses were performed with IBM SPSS® version 25 (IBM 
Corporation, Armonk, USA). P-values < 0.05 were defined as 
statistically significant.
Results
We performed 589 drug allergy workups, including 528 DCT 
and 179 sessions of ST, in 496 patients. During the study period, 
we had 72 (15%) patients with drug allergy diagnosis confirmed 
with ST or DCT. Seventy one percent (n = 51) were female with 
a mean (SD) age of 34 (21) years; 21 (29%) were < 18 years. 
Two patients had confirmed allergy to more than one drug 
(maximum 3), totalling 75 drug allergies diagnosed. 
Characteristics of the index reactions
The characteristics of the index reactions are described in table 
I. About half of the reactions were caused by betalactams (45%, 
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Table I - Characteristics of the index reactions, including stratification by the diagnostic procedure that confirmed drug allergy. When more 
than one reaction was reported for the same drug, the most recent was included. ST were performed in 31 (41%) of the included reactions.
Total Procedure that confirmed diagnosis
                            ST1                       oral DCT
(n = 75)
done 
(n = 31)
positive 
(n = 16)
(n = 59)
n (%) n n % n %
Drug involved / suspected
penicillins 34 (45) 15 7 (44) 27 (46)
other antibiotics2 12 (16) 7 5 (31) 7 (12)
paracetamol 4 (5) 2 0 (0) 4 (7)
NSAIDs 19 (25) 1 0 (0) 19 (32)
other drugs3 6 (8) 6 4 (25) 2 (3)
Time since last reaction
≤ 12 months 43 (67) 20 11 (73) 32 (66)
12 to 36 months 7 (11) 2 2 (13) 5 (10)
36 to 120 months 7 (11) 3 1 (7) 6 (12)
≥ 120 months 7 (11) 5 1 (7) 6 (12)
Symptoms
Cutaneous 71 (97) 30 15 (94) 56 (98)
urticaria4 and/or angioedema 53 (73) 23 14 (88) 39 (68)
maculopapular exanthem 18 (25) 6 0 (0) 18 (32)
fixed drug eruption 2 (3) 0 0 (0) 2 (4)
Respiratory 19 (26) 10 6 (40) 13 (23)
lower airways 18 (25) 9 6 (43) 12 (21)
upper airways (including 
laryngeal)
7 (10) 2 0 (0) 7 (12)
Cardiovascular 8 (11) 7 6 (38) 2 (4)
hypotension / collapse 8 (11) 7 6 (38) 2 (4)
Gastrointestinal 4 (56) 4 0 (0) 4 (7)
Other / unspecific 7 (10) 2 2 (13) 5 (9)
Severity, considering ref. (23)
grade 1 48 (68) 16 7 (44) 41 (75)
grade 2 3 (4) 1 0 (0) 3 (6)
grade 3 12 (17) 7 3 (19) 9 (16)
grade 4 0 (0) 0 0 (0) 0 (0)
grade 5 8 (11) 7 6 (38) 2 (4)
Time of reaction onset
≤ 1 hour 23 (33) 15 14 (93) 9 (16)
1 - 2 hours 5 (7) 3 1 (7) 4 (7)
2 - 6 hours 5 (7) 2 0 (0) 5 (9)
6 - 48 hours 12 (17) 3 0 (0) 12 (22)
> 48 hours 25 (36) 6 0 (0) 25 (46)
Previous reaction with same / 
related drug
33 (46) 11 3 (19) 30 (54)
1Includes skin prick tests and intradermal tests; 2Including cephalosporins, ciprofloxacin, cotrimoxazole, levofloxacin, minocycline, nitrofurantoin, vancomycin; 
3Including albendazole, atropine, betamethasone, cisatracurium, influenza vaccine, patent blue; 4Includes urticaria and/or erythema-warmth and/or pruritus, other 
than localized at the injection site (23). NSAID, nonsteroidal anti-inflammatory drug.
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n = 34 penicillins, and 5%, n = 4 cephalosporins). Two thirds of 
the patients had the last reaction to the culprit drug in the past 
12 months and about half reported at least another previous 
reaction with the same or a related drug. Almost all patients 
reported cutaneous symptoms, one quarter respiratory involve-
ment, and one tenth had hypotension and/or collapse; sixty-one 
percent (n = 46) of the reactions presented with exclusive cu-
taneous symptoms. Most reactions presented grade 1 severity; 
eight (11%) were grade 5. One third of the index reactions oc-
curred in the first hour after drug intake. Two patients had no 
information regarding symptoms and timing of the index reac-
tion: one child with asthma that had confirmed anaphylaxis to 
paracetamol and tested ibuprofen to exclude possible cross-re-
activity; another patient did not remember any characteristic of 
the previous reaction.
Description of the diagnostic procedures performed
Two (3%) drug allergies were confirmed by skin prick tests and 
14 (19%) by intradermal tests. Fifty-nine (78%) diagnoses were 
made by oral DCT. None of these patients performed patch tests. 
Characteristics of the index reactions stratified by the diag-
nostic procedure that confirmed drug allergy are presented in 
table I. More than half of the ST were performed in patients 
with very immediate (< 1 hour) index reactions and almost all 
were positive. No patient with a reaction beginning more than 
2 hours after drug intake had positive ST. Otherwise, 75% of 
the patients with grade 5 reactions had diagnosis confirmed 
by positive ST. 
Fifty-four (92%) DCTs were performed with diagnostic in-
tent. The other five DCTs intended to find a suitable alterna-
tive within the class of nonsteroidal anti-inflammatory drugs 
(NSAID). Two of these patients presented chronic urticaria 
with multiple NSAID intolerance, including to selective COX-
2 inhibitors (meloxicam and etoricoxib); as both of them had 
indication to take NSAID due to comorbid diseases, we decided 
to perform the DCT under preventive treatment with anti-his-
tamine ± montelukast to increase the odds of finding a suitable 
alternative strategy that could give an answer to their need of 
NSAID intake. Nevertheless, even with this preventive strategy, 
the DCT were positive.
All DCTs were performed using multistep protocols, with at 
least three predicted steps (maximum 7 steps). The number of 
predicted steps was not significantly and independently asso-
ciated with symptoms, severity or time of onset of the index 
reaction, but was significantly associated with the drug tested 
(p = 0.033). DCTs with penicillins had the highest proportion 
of procedures with at least 6 predicted steps (65% vs. 29% with 
other antibiotics, vs. 26% with NSAIDs vs. 0% with parac-
etamol and other drugs; p = 0.013). 
Description of DCTs results 
Six (10%) DCTs were considered positive and interrupted during 
the up-dosing phase. In these DCTs, the reaction occurred at 4 
to 45% of the predicted cumulative dose; two patients had pos-
itive DCT with less than 10% of the predicted dose. The pro-
portion of missed steps ranged from 17 to 67% of the predicted. 
Ninety percent (n = 53) of the DCTs had the up-dosing phase 
completed. Thirteen (22%) were positive during the watching 
period and 40 (68%) after day ward discharge (at least 5 hours 
after the last supervised dose intake). Thirty-four patients had 
extended DCT, maintaining drug intake in the days after dis-
charge; the median time to reaction was 5.5 days (maximum 11 
days). About two thirds (n = 37) of the DCT reactions occurred 
within the same time period reported for the index. However, 
15 (27%) were faster during DCT. Five (9%) reactions with in-
dex onset between 2 and 48 hours occurred within the first hour 
of the last drug intake during DCT. No reaction with index 
onset > 48 hours had symptoms within the first 2 hours. 
A description of the symptoms presented during the DCT is 
presented in table II. Almost all patients presented cutaneous 
symptoms, with a complete agreement with the index reaction. 
However, the specific type of cutaneous reaction had low agree-
ment (except for fixed drug eruption). Cardiovascular symp-
toms were present in only one patient. 
Seventy-two percent (n = 41) of the DCT reactions were grade 
1; only one patient had a grade 5 reaction. Eighty percent (n = 
44) of the DCT reactions were of similar severity grade as index 
reactions. Six (11%) had higher severity during DCT; the larg-
est variation (from a grade 1 index reaction to a grade 4 DCT 
reaction) occurred in one patient that reported a mild cutaneous 
reaction to penicillin more than 10 years before the DCT. 
Predictors of DCT outcome during up-dosing - exploratory analyses
The characteristics of patients that interrupted DCT are pre-
sented in table III. 
DCTs that were interrupted during up-dosing were performed 
with NSAIDs, paracetamol and levofloxacin; no penicillin DCT 
was positive/interrupted during up-dosing. All patients that in-
terrupted DCT before reaching the cumulative dose reported 
lower airways symptoms (p < 0.001) and very immediate index 
reactions (p < 0.001) with at least grade 3 severity. 
No significant associations were found between DCT out-
come during up-dosing and gender (p = 0.658), age group (p 
= 0.653), time since last reaction (p = 0.682), another or index 
reaction with cutaneous (0.754), cardiovascular (0.169) or gas-
trointestinal (0.315) symptoms.
All variables identified as being significantly associated with 
DCT outcome (table III) were included in the CART analysis 
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Table II - Symptoms present at the DCT and comparison with the reported index reactions. Two patients had missing information regard-
ing the index reaction.
Comparison with index reaction
Total 
(n = 59)
concordant discordant
kappa
present absent present in index present in dct
n (%) n % n % n % n %
Cutaneous 58 (98) 56 (98) 1 (2) 0 (0) 0 (0) 1.000
urticaria1 and/or angioedema 36 (61) 20 (35) 15 (26) 8 (14) 14 (25) 0.231
maculopapular exanthem 26 (44) 16 (28) 29 (51) 2 (4) 10 (18) 0.565
fixed drug eruption 2 (3) 2 (4) 55 (97) 0 (0) 0 (0) 1.000
Respiratory 16 (27) 11 (19) 41 (72) 2 (4) 3 (5) 0.757
lower airways 6 (10) 5 (9) 45 (79) 7 (12) 0 (0) 0.530
upper airways (including 
laryngeal)
12 (20) 5 (9) 45 (79) 2 (4) 5 (9) 0.519
Cardiovascular 1 (2) 0 (0) 54 (95) 2 (4) 1 (2) 0.024
Gastrointestinal 1 (1) 1 (2) 53 (93) 3 (5) 0 (0) 0.383
1Includes urticaria and/or erythema-warmth and/or pruritus, other than localized at the injection site (23).
Table III - Patients’ characteristics according to the DCT outcome during the up-dosing phase (interrupted vs. completed). Two patients 
had no information regarding the symptoms of index reaction.
DCT outcome during up-dosing1
interrupted (n = 6) completed (n = 53) p-value
n % n %
Gender, female 4 (67) 39 (74) 0.658
Age group, < 18 years old 1 (17) 19 (36) 0.653
Drug involved 0.026
penicillins 0 (0) 27 (51)
other antibiotics2 1 (17) 6 (11)
paracetamol 2 (33) 3 (4)
NSAIDs 3 (50) 16 (32)
other drugs3 0 (0) 2 (4)
Time since last reaction 0.682
≤ 12 months 3 (60) 29 (66)
12 to 36 months 1 (20) 5 (9)
36 to 120 months 1 (20) 5 (11)
≥ 120 months 0 (0) 6 (14)
Symptoms, index reaction
Cutaneous 5 (100) 51 (98) 0.754
urticaria4 and/or angioedema 5 (100) 34 (65) 0.112
80 A.M. Pereira, M. Couto, M. Pereira, L. Araújo
as possible predictors. CART identified the timing (≤ 1hour vs. 
> 1 hour) and severity (grade ≤ 2 vs. grade ≥ 3) of the index reac-
tion as the most important predictors of DCT outcome during 
up-dosing (figure 1). The final decision tree presented a classi-
fication accuracy of 98.3%, with only one patient misclassified; 
all patients that had the DCT interrupted during up-dosing 
were correctly identified. 
Discussion
In this study, the prevalence of ST or DCT-based allergy diag-
nosis was 15%. Most index reactions were mild, presenting only 
cutaneous symptoms and beginning more than one hour after 
drug intake. Seventy-eight percent of the diagnoses were based 
on DCT. All DCTs were performed using multistep protocols 
with at least three predicted steps; the number of DCT steps 
was associated with the drug tested but not with symptoms, se-
verity or time of index reaction onset. Although most DCT re-
actions were mild, 11% were more severe than reported for the 
index reaction. Only 10% of the DCTs were considered positive 
and interrupted during up-dosing; in about 70% of the DCTs 
the reaction begun at least 5 hours after the last supervised drug 
intake. The timing (≤ 1 hour vs. > 1 hour) and severity (grade ≤ 
2 vs. grade ≥ 3) of the index reaction were the most important 
predictors of DCT outcome during up-dosing.
Strengths and limitations
To our knowledge, this is the first study specifically assessing 
predictors of DCT outcome during the up-dosing phase. Hav-
ing a good prediction rule for the outcome of the supervised 
up-dosing phase of DCT can support the development of short-
DCT outcome during up-dosing1
interrupted (n = 6) completed (n = 53) p-value
maculopapular exanthem 0 (0) 18 (35) 0.168
fixed drug eruption 0 (0) 2 (4) 1.000
Respiratory 5 (100) 8 (15) < 0.001
lower airways 5 (100) 7 (14) < 0.001
upper airways (including laryngeal) 2 (40) 5 (10) 0.109
Cardiovascular 1 (20) 1 (2) 0.169
hypotension / collapse 1 (20) 1 (2) 0.169
gastrointestinal 1 (20) 3 (6) 0.315
Other / unspecific 1 (20) 4 (8) 0.379
Severity index, considering ref. (23) < 0.001
grade 1 0 (0) 41 (82)
grade 2 0 (0) 3 (6)
grade 3 4 (80) 5 (10)
grade 4 0 (0) 0 (0)
grade 5 1 (20) 1 (2)
Time of index reaction onset < 0.001
≤ 1 hour 6 (100) 3 (6)
1 - 2 hours 0 (0) 4 (8)
2 - 6 hours 0 (0) 5 (10)
6 - 48 hours 0 (0) 12 (25)
> 48 hours 0 (0) 25 (51)
Another previous reaction with same / related drug 4 (80) 26 (51) 0.358
1The up-dosing phase of the DCT was considered completed if the target cumulative dose was reached; 2Including cephalosporins, ciprofloxacin, cotrimoxazole, 
levofloxacin, minocycline, nitrofurantoin, vancomycin; 3Including albendazole, atropine, betamethasone, cisatracurium, influenza vaccine, patent blue; 4Includes 
urticaria and/or erythema-warmth and/or pruritus, other than localized at the injection site (23). NSAID, nonsteroidal anti-inflammatory drug.
Table III - (continued)
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er and personalized DCT protocols in patients with low risk 
of reaction, decreasing the cost and time of these diagnostic 
procedures without increasing the risk of higher severity DCT 
reactions. However, this study is limited by the retrospective na-
ture, with data collected from electronic and paper-based data 
recording systems. Moreover, the small sample size, especially 
in the analyses using comparisons between groups of DCT out-
come and CART, makes these results only exploratory and in 
need of careful interpretation. The selection of patients with 
confirmed drug allergy, which would not be possible before 
diagnostic assessment and is inverted comparing to real-life, 
makes this study less directly applicable to clinical practice. 
However, we considered that it might be more effective to de-
scribe and evaluate predictors of DCT outcome in patients that 
were at “true” risk of interrupting DCT due to reaction. The 
inclusion of all patients, irrespective of the results of diagnostic 
assessments, although closer to the usual diagnostic reasoning, 
would increase the noise and decrease the focus in those pa-
tients. Nevertheless, before clinical use, these results need vali-
dation in a more comprehensive sample including patients with 
and without confirmed drug allergy. 
The inclusion of patients presenting mostly mild reactions and 
predominantly with betalactams might also influence our re-
sults. Yet, these were the available patients in our centre and 
we believe they represent the usual clinical practice in most 
allergy units. 
Interpretation of study findings and comparison with the literature
Previous studies, in various settings and populations, with 
diverse drugs and based on different diagnostic approaches, 
showed a prevalence of confirmed drug allergy in subjects with 
suspected drug reactions ranging from 3 to 27% (28-31). Our 
prevalence is higher than those reported in general settings 
(around 6%) (28,31), but is in line with a few studies held in 
specialized allergy units (30). 
In our study, most patients presented the last reaction to the cul-
prit drug within the previous 12 months. This puts most patients 
within the best time interval to perform the diagnostic assess-
ment of suspected drug allergies. Indeed, a loss of sensitivity to 
drugs over time has been reported for IgE-mediated reactions 
(32), and after a time-interval of more than 6-12 months, some 
drug tests may already give negative results. Moreover, when the 
time interval between the reaction and the allergy assessment is 
longer, history is often less reliable and there is a lack of accurate 
information: the chronology is imprecise, the clinical manifesta-
tions are heterogeneous, making drug causality assessment more 
difficult to ascertain (6,33). The short time interval between the 
index reaction and diagnostic assessment might have contributed 
to the low number of patients with missing data regarding the 
characteristics of the previous reactions. However, the agreement 
between the characteristics of the index and DCT reactions was 
only fair, especially regarding cardiovascular, gastrointestinal and 
Figure 1 - Decision tree for DCT outcome during up-dosing (interrupted vs. completed). 
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specific cutaneous symptoms, suggesting that symptoms may be 
interpreted differently at different times/by different assessors 
or that DCT reaction might vary from the index reaction, even 
when it is recent; these findings are in line with another recent 
study (34). Nevertheless, most patients presented DCT reactions 
of similar severity as the index. 
There are several difficulties regarding the choice of the best di-
agnostic approach to a specific patient, namely when to perform 
ST and which DCT protocol should be used. One of the con-
troversies is related to the cut-off that should be used to differ-
entiate immediate from nonimmediate reactions (2-5). In our 
study we chose to assess drug allergy diagnoses without a priori 
stratification by timing of the index reaction. This allowed us 
to explore the best cut-off to identify patients at higher risk of 
early DCT reaction (≤ 1 hour vs. > 1 hour), which, in our study, 
follows the classification proposed by Romano et al. (2).
In the past decade, several studies have evaluated prolonged 
DCTs to better detect nonimmediate DHRs with penicillin an-
tibiotics (12-18). A recent study used a similar approach also 
in patients with non-severe immediate amoxicillin reactions be-
ginning with an office-based supervised 3-steps DCT followed 
by a 4-day DCT; this study showed that this is a safe and effec-
tive way to rule out non-severe immediate and nonimmediate 
amoxicillin allergy, and ensures better compliance with future 
penicillin use (35). In that study, only 2.3% among the 130 pa-
tients who underwent a DCT presented a reaction on their ini-
tial visit (even if 20% had a suspected immediate reaction based 
on the clinical history) and all the remaining had to undergo a 
further ambulatory course of antibiotic continued at home (35). 
However, even in these studies, the diagnostic approach includ-
ed a long, ≥ 3 steps, office-based initial DCT. Only a few studies 
assessed the safety of shorter (1 or 2-step) DCT. Iammatteo M 
et al. (36) performed a retrospective study of 497 one or two-
step test doses and compared the outcomes with those of multi-
step challenges. They included patients tested with several drug 
classes and found that one or two-step DCT were safe and that 
multistep challenges did not confer added safety. Mawhirt SL et 
al. (34) also reported that full dose challenges presented similar 
safety to multistep DCT in patients with immediate reactions 
to antibiotics. Our results, with most reactions occurring after 
the target dose was reached, irrespective of the tested drug, sup-
port that these shorter DCT/test doses might be effective and 
safe way to diagnose drug allergy, at least in some patients. 
In fact, DCT are long and expensive (9-11) diagnostic pro-
cedures that would benefit from a better patient stratification 
through the identification of predictors of early DCT reaction. 
We found timing and severity of index reactions as the best pre-
dictors of DCT outcome during up-dosing. Indeed, timing and 
severity of the index reaction are traditionally used to stratify di-
agnostic procedures to perform in patients with suspected drug 
allergy (3,4,10). However, besides controversial classifications, 
there are no clearly defined cut-offs and practical decision rules 
to apply when selecting the diagnostic approach to follow in a 
specific patient. Our CART analysis, although exploratory, al-
lowed the development of a decision tree that could be used to 
correctly identify patients that had the DCT interrupted. Our 
results suggest that, in most patients, DCT protocol could be 
more adapted to the patient and index reaction characteristics 
and less dependent on the drug. However, further studies com-
paring multistep with full dose or two-steps DCT protocols are 
warranted. The predictors of DCT outcome during up-dosing, 
found in our exploratory analysis, should be further tested in a 
different sample and validated into a prospective comparative 
study in real-life conditions.
Conclusions
Most drug allergy diagnoses were based on drug challenges, per-
formed with multistep protocols dependent on the culprit drug. 
Only one tenth of the challenge reactions occurred during the 
up-dosing phase. The predictors of DCT interruption during 
up-dosing identified in the CART analysis can support the de-
velopment of more personalized DCTs protocols but need fur-
ther research before being applied into clinical practice.
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